The U.S. Drug Enforcement Administration (DEA) has formally reclassified medical cannabis from Schedule I to Schedule III under the Controlled Substances Act. This federal medical cannabis reclassification, finalized on April 22 by acting U.S. Attorney General Todd Blanche, eliminates a significant federal tax penalty that has impacted the economics of the medical cannabis industry for decades, as reported by .
This policy adjustment follows a December executive order from President Donald Trump, which directed federal agencies to expedite the rescheduling process. The change moves medical cannabis into the same schedule as substances like ketamine, testosterone, and Tylenol with codeine, marking a shift in federal policy toward regulated medical cannabis programs, building on earlier coverage regarding federal medical cannabis reclassification.
Implications for Federal Tax Code 280E
The primary immediate effect of the medical cannabis reclassification is the release of medical cannabis businesses from Section 280E of the federal tax code. Enacted by Congress in 1982, Section 280E prohibited businesses trafficking controlled substances from deducting ordinary business expenses, with the exception of the cost of goods sold. This provision was originally introduced in response to a tax court case where a drug trafficker successfully argued for business expense deductions.
Under Section 280E, medical cannabis businesses faced dramatically higher federal tax rates than other industries. While the standard corporate federal income tax rate is 21% of net profits, cannabis businesses were estimated to pay effective tax rates of up to 70% due to the inability to claim deductions or write off expenses. Dave Brown, a cannabis consultant and co-owner of Willow Pharmacy dispensaries, noted that this made it “exceptionally costly to own a cannabis business,” according to .
Differential Impact on Industry Segments
Prior to the reclassification, the implications of 280E disproportionately affected dispensaries and retailers more severely than producer-processors. This was because businesses could still deduct the cost of the goods they sold, but these costs constitute a smaller proportion of overall expenses for dispensaries compared to cultivation and processing operations. With the removal of 280E, dispensaries will now be able to deduct a full suite of operational expenses, including:
- Rent or mortgages
- Employee payroll
- Marketing costs
- Utilities
- Equipment and asset depreciation
Brown stated that the intention for his dispensaries would be “to declare the full suite of deductions that any other retail business is able to declare from their federal taxes.”
Louisiana Market Dynamics
The tax adjustment arrives as Louisiana’s medical cannabis industry has experienced significant expansion. According to Louisiana Department of Revenue reports, medical cannabis producers in the state sold an estimated $90.9 million worth of cannabis to dispensaries in the year ending June 30, 2025. This represents a 77% increase compared to the prior fiscal year.
Patient enrollment in Louisiana’s medical program has also grown substantially, nearing 150,000 residents as of early this year. This figure reflects a doubling of patient numbers in less than two years, as presented by John Davis, president of Good Day Farms Louisiana, at a February meeting of the Rotary Club of Baton Rouge.
Good Day Farms Louisiana, which produces over 70% of the state’s legal cannabis, effectively operates a majority of Louisiana’s 27 medical marijuana dispensaries. While the company acknowledges the significance of the reclassification, Davis stated it was “premature to speculate on specific operational or economic impacts at this stage.” Ilera Holistic, the state’s other licensed producer, declined to comment, citing ongoing evaluation of the legal implications.
Considerations for Multi-Use Markets
While the tax cut benefits all businesses involved in the production or sale of medical cannabis, its distribution is not uniform across the country. In the 24 states where cannabis is sold without a prescription, many businesses operate both medical and adult-use cannabis product sales from the same storefront. This scenario presents ongoing accounting challenges, as some business activities within the same location may still be considered illicit by the federal government.
However, this complexity does not affect Louisiana, Arkansas, Mississippi, or Florida, where medical cannabis remains the only legal form of cannabis. In these states, businesses will not face the same hybrid tax regime issues. Given the concentrated ownership structure of the Louisiana medical cannabis market, with only two licensed producers and one operating a majority of dispensaries, the financial benefits of this reclassification will accrue to a relatively small number of entities.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
